Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Mazyar Shadman et al.|Clinical Cancer Research|2020Cited by 115
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E. Roeker, Anthony R. Mato, Christopher P. Fox et al.|Clinical Cancer Research|2019Cited by 90
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agentsLindsey E. Roeker, Anthony R. Mato, Peter Dreger et al.|Blood Advances|2020Cited by 86